About Daniel Tang

Dr. Tang Xiaodong is the CEO of Yuanyin Biopharmaceuticals. He has more than 25 years of experience in the field of new drug research and development, especially in the field of cancer antibody targeted therapy . Board Member), General Manager ( GM ) of ICON Asia Pacific , and has long been engaged in DMPK and GLP bioanalysis in Pfizer, USA, and his participation includes bringing 7 projects to IND and 2 projects to NDA . Dr. Tang is a Beijing Haiju engineering talent and has participated in the publication of more than 50 papers. He is a member of the Steering Committee of the Global Bioanalytical Consortium ( GBC ) and participated in the writing of the draft guidelines for the validation of bioanalytical methods in the 2015 edition of the Chinese Pharmacopoeia. He has also served as Chairman of the Analytical Science and Pharmaceutical Quality Group of the International Federation of Pharmaceuticals ( FIP ) and on the editorial board of the European journal “Bioanalysis” . Dr. Tang holds a bachelor’s degree in biochemistry from Peking University, a master’s degree in business administration from the University of Michigan, and a Ph.D. in analytical chemistry from George Washington University.